{"product_id":"slu-pp-332-pen-test","title":"SLU-PP-332 | 1,5 Mg\/ 3 ml Pen","description":"\u003cp\u003eSLU-PP-332 is an investigational mitochondrial\/energy-focused research compound explored for its role in oxidative metabolism and endurance-related bioenergetic endpoints. It is commonly discussed in the context of nuclear receptor signaling that influences mitochondrial biogenesis programs, substrate utilization, and fatigue-resistance markers in preclinical models. Information on this page is provided for scientific and educational context only and does not represent medical guidance or therapeutic claims.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSupports\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eMitochondrial energy output frameworks associated with oxidative phosphorylation efficiency markers.\u003c\/li\u003e\n\u003cli\u003eFatigue-resistance endpoints tracked through muscle bioenergetic and recovery readouts in models.\u003c\/li\u003e\n\u003cli\u003eMetabolic flexibility context linked to fatty acid oxidation and substrate-shift signaling.\u003c\/li\u003e\n\u003cli\u003eMitochondrial biogenesis programs associated with PGC-1α\/NRF\/TFAM pathway readouts.\u003c\/li\u003e\n\u003cli\u003eOxidative-stress balance markers monitored via ROS and redox-related assay endpoints.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eDescription\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eSLU-PP-332\u003c\/strong\u003e is a research compound frequently described as an agonist within nuclear receptor signaling frameworks that regulate mitochondrial function and systemic energy utilization. In experimental design, it is positioned to study how transcriptional control of oxidative metabolism affects endurance phenotypes, fuel preference (fat vs. glucose utilization), and mitochondrial adaptation markers in skeletal muscle and metabolic tissues.\u003c\/p\u003e\n\u003cp\u003eAcross preclinical models, SLU-PP-332 is commonly framed around increased oxidative capacity and shifts toward more oxidative muscle fiber characteristics, alongside changes in mitochondrial density and respiration-related readouts. Studies often measure downstream markers linked to mitochondrial biogenesis and electron transport chain activity, as well as substrate-oxidation signals that reflect metabolic reprogramming under controlled conditions.\u003c\/p\u003e\n\u003cp\u003eReported observations are model- and endpoint-dependent. This product is presented for research and educational context only and is not marketed as an approved therapeutic product.\u003c\/p\u003e\n\u003ch2\u003eClinical Status\u003c\/h2\u003e\n\u003cp\u003eSLU-PP-332 is primarily evaluated in preclinical and in vitro settings focused on mitochondrial performance, endurance physiology, and metabolic signaling. It is not presented here as an approved therapeutic product, and outcomes can vary substantially by study design, protocol variables, and model selection.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvidence type:\u003c\/strong\u003e\u003cbr\u003eHuman RCT ☐ | Observational ☐ | Animal ✔ | In vitro ✔ | Regulatory approval ☐\u003c\/p\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp\u003eSLU-PP-332 is commonly discussed as an activator of nuclear receptor pathways associated with mitochondrial biogenesis and oxidative metabolism programs. In model systems, downstream readouts often include increased expression of regulators such as \u003cstrong\u003ePGC-1α\u003c\/strong\u003e, \u003cstrong\u003eNRF-1\u003c\/strong\u003e, and \u003cstrong\u003eTFAM\u003c\/strong\u003e, alongside changes in mitochondrial transcription and electron transport chain component markers. These adaptations are used to frame hypotheses around improved oxidative phosphorylation capacity and sustained ATP availability in endurance settings.\u003c\/p\u003e\n\u003cp\u003ePreclinical work also describes shifts in β-oxidation signaling and metabolic flexibility markers, sometimes discussed alongside AMPK-related pathway readouts. Reported changes in ROS\/oxidative-load metrics are frequently evaluated in parallel to assess mitochondrial efficiency and oxidative stress balance under experimental conditions.\u003c\/p\u003e\n\u003ch2\u003eBenefits\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eSelective PPARδ Activation and Metabolic Optimization\u003c\/b\u003e:\u003cbr\u003eSlu-pp-332 is studied as a\u003cspan\u003e \u003c\/span\u003e\u003cb\u003eselective agonist of peroxisome proliferator-activated receptor delta (PPARδ)\u003c\/b\u003e, a key regulator of lipid and glucose metabolism. By activating PPARδ pathways, it enhances energy utilization in skeletal muscle and promotes a metabolic shift from glucose to fatty acid oxidation, making it an advanced subject in mitochondrial and endurance research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEnhanced Fat Oxidation and Energy Efficiency\u003c\/b\u003e:\u003cbr\u003ePreclinical data indicate that Slu-pp-332 increases\u003cspan\u003e \u003c\/span\u003e\u003cb\u003efatty acid β-oxidation\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eand mitochondrial respiration, resulting in improved ATP generation and endurance performance. This metabolic reprogramming supports greater energy efficiency and resilience during prolonged activity, aligning it with research into metabolic performance enhancement and fatigue resistance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eImproved Muscle Endurance and Exercise Capacity\u003c\/b\u003e:\u003cbr\u003eSlu-pp-332 has been shown to\u003cspan\u003e \u003c\/span\u003e\u003cb\u003eimprove exercise performance\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eby upregulating genes associated with oxidative muscle fibers and mitochondrial density. This shift enhances muscle fatigue resistance and promotes endurance phenotypes, making it of interest in research exploring athletic performance and cellular energy optimization.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eReduction of Fat Accumulation and Weight Gain\u003c\/b\u003e:\u003cbr\u003eIn animal studies, Slu-pp-332 administration has resulted in\u003cspan\u003e \u003c\/span\u003e\u003cb\u003edecreased body fat accumulation\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eeven under high-fat dietary conditions. Its mechanism involves elevated fatty acid catabolism and reduced lipogenesis, supporting its study as a potential modulator of weight management and metabolic balance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eImprovement of Insulin Sensitivity and Glucose Tolerance\u003c\/b\u003e:\u003cbr\u003eThrough its action on PPARδ receptors in muscle and liver tissue, Slu-pp-332\u003cspan\u003e \u003c\/span\u003e\u003cb\u003eenhances glucose uptake and insulin sensitivity\u003c\/b\u003e. Research shows improved glycemic control and lower fasting glucose levels in metabolic models, making it relevant in studies addressing insulin resistance and glucose homeostasis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEnhanced Mitochondrial Biogenesis and Cellular Respiration\u003c\/b\u003e:\u003cbr\u003eActivation of PPARδ by Slu-pp-332 stimulates\u003cspan\u003e \u003c\/span\u003e\u003cb\u003ePGC-1α signaling\u003c\/b\u003e, leading to the creation of new mitochondria and improved respiratory chain activity. This boost in mitochondrial number and function supports sustained cellular energy production and resilience under oxidative or metabolic stress conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSupport for Muscle Fiber Transformation\u003c\/b\u003e:\u003cbr\u003eSlu-pp-332 promotes a shift toward\u003cspan\u003e \u003c\/span\u003e\u003cb\u003eoxidative type I muscle fibers\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eknown for higher endurance and fatigue resistance. This fiber-type remodeling is driven by enhanced mitochondrial enzyme expression and energy utilization, providing a strong foundation for research into endurance training and muscle adaptation mechanisms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAnti-Inflammatory and Antioxidant Properties\u003c\/b\u003e:\u003cbr\u003eResearch shows that PPARδ activation by Slu-pp-332\u003cspan\u003e \u003c\/span\u003e\u003cb\u003ereduces pro-inflammatory cytokine expression\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eand upregulates antioxidant defenses, including superoxide dismutase and catalase. These effects protect tissues from inflammation-induced oxidative damage, supporting applications in metabolic and cardiovascular research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eProtection of Liver and Metabolic Organs\u003c\/b\u003e:\u003cbr\u003eIn hepatic models, Slu-pp-332 reduces\u003cspan\u003e \u003c\/span\u003e\u003cb\u003elipid accumulation and oxidative stress\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003ewhile improving liver enzyme markers. These hepatoprotective effects are attributed to enhanced β-oxidation and reduced triglyceride synthesis, highlighting its potential role in non-alcoholic fatty liver disease and metabolic syndrome research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEnhanced Cognitive and Neural Energy Metabolism\u003c\/b\u003e:\u003cbr\u003eEmerging data suggest that Slu-pp-332 may\u003cspan\u003e \u003c\/span\u003e\u003cb\u003eimprove neuronal energy metabolism\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eby increasing mitochondrial density and lipid utilization in brain tissue. This effect supports cognitive performance and neural protection under metabolic stress, forming a promising research link between PPARδ activation and neuroenergetics.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSynergy with Mitochondrial Peptides and NAD+ Precursors\u003c\/b\u003e:\u003cbr\u003eWhen combined with mitochondrial modulators such as\u003cspan\u003e \u003c\/span\u003e\u003cb\u003eMOTS-c, SS-31, or NAD+\u003c\/b\u003e, Slu-pp-332 enhances oxidative phosphorylation and systemic energy turnover. This synergistic relationship is being explored in models targeting longevity, endurance, and metabolic resilience optimization.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePotential in Longevity and Anti-Aging Research\u003c\/b\u003e:\u003cbr\u003eThrough sustained activation of metabolic and mitochondrial pathways, Slu-pp-332\u003cspan\u003e \u003c\/span\u003e\u003cb\u003esupports cellular rejuvenation and energy preservation\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eassociated with extended healthspan. Its influence on lipid metabolism, oxidative balance, and mitochondrial efficiency makes it a key compound in aging and vitality-related peptide research.\u003c\/li\u003e\n\u003cli\u003e\u003cbr\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eResearch Data\u003c\/h2\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"10\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStudy\/model\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReported effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMouse endurance models\u003c\/td\u003e\n\u003ctd\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e↑ Running time to exhaustion (+35%), ↑ ATP levels in muscle tissue\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIn vitro mitochondrial assays\u003c\/td\u003e\n\u003ctd\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e↑ OXPHOS complex activity (I-IV), ↓ ROS leakage\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRat fatigue recovery studies\u003c\/td\u003e\n\u003ctd\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e↓ Lactate accumulation, ↑ glycogen resynthesis post-exercise\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCellular oxidative stress models\u003c\/td\u003e\n\u003ctd\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e↑ GSH:GSSG ratio, ↓ lipid peroxidation markers\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMPK activation assays\u003c\/td\u003e\n\u003ctd\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e↑ p-AMPK and PGC-1α expression, ↑ mitochondrial density\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh-fat diet mouse models\u003c\/td\u003e\n\u003ctd\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e↓ Fat accumulation, ↑ β-oxidation enzyme expression\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeuronal culture models\u003c\/td\u003e\n\u003ctd\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e↑ Mitochondrial membrane potential, ↓ oxidative apoptosis\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eStack Suggestions\u003c\/h2\u003e\n\u003cp\u003eIn extended experimental designs, SLU-PP-332 is sometimes paired with:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNAD+ (redox and mitochondrial-context frameworks commonly monitored in energy studies)\u003c\/li\u003e\n\u003cli\u003eSS-31 (mitochondrial stress and membrane-stability frameworks)\u003c\/li\u003e\n\u003cli\u003eMOTS-c (metabolic signaling context in endurance-oriented study designs)\u003c\/li\u003e\n\u003cli\u003e5-Amino-1MQ (metabolic flux and lipid-handling frameworks where applicable)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStacks discussed are for experimental design only, not safety\/efficacy guidance.\u003c\/p\u003e\n\u003ch2\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp\u003eSlu-pp-332, as a research compound, may induce side effects in experimental models, primarily related to its metabolic activation. These reactions are generally mild and dose-dependent via oral administration. Monitoring is key in protocols.\u003c\/p\u003e\n\u003cp\u003eFatigue: Temporary energy fluctuations during adaptation.\u003cbr\u003eGastrointestinal Upset: Mild nausea or diarrhea at higher doses.\u003cbr\u003eHeadache: Occasional, possibly from metabolic shifts.\u003cbr\u003eMuscle Cramps: Rare, linked to enhanced activity.\u003cbr\u003eHormonal Changes: Potential minor estrogen-related effects, though non-steroidal.\u003c\/p\u003e\n\u003cp\u003eIt is crucial to note that most side effects are transient. No serious adverse events reported in preclinical; long-term safety unknown.\u003c\/p\u003e\n\u003ch2\u003eScientific References\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10801787\/\"\u003eA Synthetic ERR Agonist Alleviates Metabolic Syndrome\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eAnimal\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/www.jrenendo.com\/PDF\/jre-10-e25143.pdf\"\u003eNew hopes on “SLU-PP-332” as an effective agent for weight loss. Journal of Research in Endocrinology\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eAnimal\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0306987724001051\"\u003eCan SLU-PP-332 be a new drug to prevent COVID-19\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eIn vitro\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/ujpronline.com\/index.php\/journal\/article\/view\/1355\/1932\"\u003eSLU-PP-332 AND RELATED ERRα AS AGONISTS\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eReview\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/www.researchgate.net\/publication\/385096831_Unlocking_the_potential_slu-pp-332_and_the_future_of_exercise_Enhancement_and_Metabolic_health\"\u003eUnlocking the potential: SLU-PP-332 and the future of exercise Enhancement and Metabolic health\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eReview\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37739806\/\"\u003eA Synthetic ERR Agonist Alleviates Metabolic Syndrome\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eAnimal\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/lotilabs.com\/resources\/discover-the-benefits-and-risks-of-slu-pp-332-a-comprehensive-guide\/\"\u003eDiscover the Benefits and Risks of SLU PP 332\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eReview\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/swolverine.com\/blogs\/blog\/slu-pp-peptide-benefits-dosage-and-metabolic-effects-explained\"\u003eSLU-PP Peptide: Benefits, Dosage, and Metabolic Effects Explained\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eReview\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/revolutionhealth.org\/blogs\/news\/peptide-therapy-slu-pp-332\"\u003eSLU-PP-332: The Oral Peptide That Mimics Exercise and Boosts Metabolism\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eReview\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/www.peptidesciences.com\/peptide-research\/what-is-slu-pp-332-how-does-it-work\"\u003eWhat is SLU-PP-332? How does it Work?\u003c\/a\u003e\u003cspan\u003e \u003c\/span\u003eReview\u003cbr\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCautions\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eFor educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.\u003c\/li\u003e\n\u003cli\u003eIf you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.\u003c\/li\u003e\n\u003cli\u003eDiscontinue use if sensitivity occurs.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Peptoora","offers":[{"title":"Default Title","offer_id":61559769497930,"sku":"SM-PS-PEN-003","price":399.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0887\/1139\/7706\/files\/SLU-PP-332_15mg_3ml.png?v=1775794415","url":"https:\/\/peptoora.com\/it\/products\/slu-pp-332-pen-test","provider":"Peptoora LTD","version":"1.0","type":"link"}